Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cepheid, a molecular diagnostics company, has announced that Health Canada has issued a medical device license for its Xpert MRSA/SA skin and soft tissue test for the rapid detection of Methicillin-resistant Staphylococcus aureus and Staphylococcus aureus (typically Methicillin-sensitive) in skin and soft tissue infections.
Subscribe to our email newsletter
In less than one hour, the Xpert MRSA/SA skin and soft tissue (SSTI) test processes specimens from suspected skin and soft tissue infection swabs to determine if a patient is infected with Methicillin-resistant Staphylococcus aureus (MRSA) or SA, the company said.
The new test runs on Cepheid’s GeneXpert System, a healthcare associated infection molecular testing platform. The availability of the Xpert MRSA/SA SSTI test is expected to empower Canadian physicians and surgeons with a new tool to aid in selecting the most effective antibiotic therapy to improve patient management.
Xpert MRSA/SA SSTI is Cepheid’s fifth test to receive a Health Canada medical device license. Xpert MRSA/SA blood culture and Xpert HemosIL are currently under review.